BioSpace

CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’s

Biogen and AriBio reported wins for their respective therapies targeting Alzheimer’s disease, while Priavoid and Cognito Therapeutics missed the mark—though the latter plans to file for FDA approval based on a positive subgroup signal.

By BioSpace

1 min read
CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’s
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights